Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-cash Items (2019 - 2025)

Historic Non-cash Items for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $97.8 million.

  • Eton Pharmaceuticals' Non-cash Items rose 77336.97% to $97.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.8 million, marking a year-over-year increase of 77336.97%. This contributed to the annual value of $51.3 million for FY2024, which is 140934.03% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Non-cash Items stood at $97.8 million for Q3 2025, which was up 77336.97% from $4.4 million recorded in Q2 2025.
  • Eton Pharmaceuticals' Non-cash Items' 5-year high stood at $97.8 million during Q3 2025, with a 5-year trough of $634000.0 in Q2 2024.
  • Its 5-year average for Non-cash Items is $13.9 million, with a median of $3.4 million in 2022.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Non-cash Items plummeted by 8180.8% in 2021, and later skyrocketed by 140934.03% in 2024.
  • Over the past 5 years, Eton Pharmaceuticals' Non-cash Items (Quarter) stood at $2.1 million in 2021, then skyrocketed by 33.05% to $2.8 million in 2022, then increased by 21.88% to $3.4 million in 2023, then skyrocketed by 1409.34% to $51.3 million in 2024, then skyrocketed by 90.52% to $97.8 million in 2025.
  • Its Non-cash Items stands at $97.8 million for Q3 2025, versus $4.4 million for Q2 2025 and $46.6 million for Q1 2025.